Back to results

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Primary Purpose

Cutaneous Lupus Erythematosus (CLE)

Status

Completed

Phase

Not Applicable

Locations

United States

Study Type

Interventional

Intervention

Lenalidomide

About this trial

This is an interventional treatment trial for Cutaneous Lupus Erythematosus (CLE) focused on measuring Cutaneous Lupus Erythematosus, CLE, lenalidomide, revlimid, thalidomide derivative, drug, lupus

Eligibility Criteria

18 Years - 100 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Subjects must understand and voluntarily sign Informed Consent and HIPAA forms.
Males and females over the age of 18 at the time of signing informed consent form.
Able to adhere to the study visit schedule and other protocol requirements
Subjects must have biopsy proven Cutaneous Lupus Erythematosus (CLE) either in the form of Discoid Lupus Erythematosus (DLE) or Subacute Lupus Erythematosus (SCLE), with or without systemic involvement.
Subjects must have grade II erythema in at least three skin locations as defined by the Cutaneous Lupus Activity and Severity Index (CLASI).
Subjects must have failed standard treatment with hydroxychloroquine (Plaquenil) for up to three months.
Female subjects who are not pregnant.
Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional method AT THE SAME TIME, at least 28 days before starting to take lenalidomide (Revlimid®). FCBP must also agree to ongoing pregnancy testing. Males must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure.
If pregnancy or a positive pregnancy test is noted in a study subject or in the partner of a male study subject during study participation, the study drug must be discontinued immediately.

Exclusion Criteria:

Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form.
Female subjects who are pregnant, plan to be pregnant during the study, or who are breastfeeding.
Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk for study participation, or confounds the ability to interpret data from the study.
Use of any other experimental drug or therapy within 28 days of baseline.
Known hypersensitivity to thalidomide.
The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.
Prior history of deep vein thrombosis (DVT).
Prior history of pulmonary embolus (PE).
Known positive for HIV viral DNA by qPCR.
Positive hepatitis B surface antigen, or hepatitis C.
Platelet count < 50,000/mcL.
Absolute neutrophil count < 750/mcL
Lymphopenia < 500/mcL.
Have current signs or symptoms of severe progressive or uncontrolled renal disease (creatinine ≥1.5 x ULN).
If female, unwillingness to use one highly effective method and one additional method of birth control.
If male, unwillingness to use a latex condom during intercourse with females of childbearing potential.
Continued therapy with thalidomide.

Sites / Locations

Hospital of the University of Pennsylvania, Department of Dermatology

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Arm Label

Lenalidomide

Lenalidomide 2

Arm Description

Open label lenalidomide received.

Outcomes

Primary Outcome Measures

Cutaneous Lupus Area and Severity Index (CLASI)

The Cutaneous Lupus Area and Severity Index (CLASI); range of disease activity is 0-70. Lower scores reflect less activity.

Secondary Outcome Measures

Number of Participants With Change in IFN and CD4 Levels at 6 Weeks

CXCL10, an interferon-inducible chemokine, and immunophenotyping by immunostaining. Measurement of interferon-inducible genes from peripheral blood mononuclear cells before and after treatment.

Physician Global Assessment (PGA) for Skin

General skin scores were recorded on a 10 cm visual analogue scale at each visit. At each visit on scale 0-10, 0 corresponding to worst skin condition imaginable and 10 to perfect health.

Patient General Assessment (PtGA) for Skin

General skin scores were recorded by the patient on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to worst skin condition imaginable and 10 to perfect health.

Pain in Skin

Pain in skin was recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no pain and 10 to pain as bad as you can imagine.

Itch in Skin

Itch scores were recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no itch and 10 to itch as bad as you can imagine.

Fatigue

Fatigue scores were recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no fatigure and 10 to fatigue as bad as you can imagine.

Skindex Symptoms

Skindex symptoms scores are scored 1-5 and then normalized to 100, with a higher score corresponding to a worse impression. The absence of symptom impact on QoL is scored as "20" (this is represented as a 1 on the 1-5 scale. The worst impact of symptoms on QoL is 100. This is represented as a 5 on the 1-5 scale.

Skindex Function

Skindex function scores are scored 1-5 and then normalized to 100, with a higher score corresponding to a worse impression. The absence of function impact on QoL is scored as "20" (this is represented as a 1 on the 1-5 scale. The worst impact of function on QoL is 100. This is represented as a 5 on the 1-5 scale.

Full Information

NCT ID

NCT00633945

First Posted

March 4, 2008

Last Updated

February 7, 2023

Sponsor

University of Pennsylvania

Collaborators

Celgene Corporation

1. Study Identification

Unique Protocol Identification Number

NCT00633945

Brief Title

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

Official Title

Evaluation of Lenalidomide (REVLIMID®) in Cutaneous LE: A Prospective, Non Controlled, Open Label Pilot Study to Evaluate the Off-Label Use of the FDA-approved Drug Lenalidomide (REVLIMID®) in Patients With Cutaneous Lupus Erythematosus

Study Type

Interventional

2. Study Status

Record Verification Date

February 2023

Overall Recruitment Status

Completed

Study Start Date

November 2007 (undefined)

Primary Completion Date

July 2009 (Actual)

Study Completion Date

October 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

University of Pennsylvania

Collaborators

Celgene Corporation

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This study is being conducted to evaluate the safety and effectiveness of lenalidomide (Revlimid®) in subjects with Cutaneous Lupus Erythematosus (CLE). The study drug will be used in an off-label indication to treat 6 subjects for 12 months each. Men and women over the age of 18, who have a biopsy proven diagnosis of CLE and who have failed standard treatment, will be included in the study.

Detailed Description

Cutaneous lupus erythematosus (CLE) is a chronic and often disabling disease which affects the skin. Many patients experience scarring and inflammation of the skin, which often occur on the face. Moderate to severe CLE is most frequently treated with antimalarial drugs such as hydroxychloroquine, quinacrine or chloroquine. Up to 70% of CLE patients treated with antimalarials experience a beneficial clinical response, while the remainder of patients show no response or continue to experience progression of the disease. Thalidomide has been used successfully in such patients, with up to 75% clinical response rate in refractory CLE patients. However, thalidomide is a known teratogen and can cause severe birth defects, including short, malformed limbs and damage to peripheral nerves in the extremities, requiring patients to be monitored for pregnancy. In addition, up to 25% of patients on thalidomide develop peripheral neuropathy. A new drug, lenalidomide (REVLIMID®), an analogue of thalidomide, has been developed to treat neoplastic and inflammatory conditions, including various oncologic conditions such as multiple myeloma, myelodysplastic syndrome and solid tumors. Unlike thalidomide, lenalidomide (REVLIMID®) is not known to cause the extent of serious side effects caused by thalidomide; however, it must also be monitored for side effects and be distributed under the RevAssist program authorized by the drug manufacturer, Celgene Corporation. The primary goal of this investigator-initiated, small pilot study is to evaluate the safety and effectiveness of lenalidomide (REVLIMID®) in CLE subjects using measurements such as the CLASI (Cutaneous Lupus Activity and Severity Index). The study drug will be used in an off-label indication to treat 6 subjects, for whom lenalidomide (REVLIMID®) will be provided at no cost by the drug manufacturer. Men and women over the age of 18, who have a biopsy proven diagnosis of refractory CLE and who have failed standard treatment with hydroxychloroquine for up to three months, will be included in the study. Secondarily, the study will evaluate the biologic effects of lenalidomide on pathogenic and immunologic mechanisms of the CLE disease process during the treatment period by collecting skin specimens (biopsies) and blood samples.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Cutaneous Lupus Erythematosus (CLE)

Keywords

Cutaneous Lupus Erythematosus, CLE, lenalidomide, revlimid, thalidomide derivative, drug, lupus

7. Study Design

Primary Purpose

Treatment

Study Phase

Not Applicable

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

5 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Lenalidomide

Arm Type

Experimental

Arm Description

Open label lenalidomide received.

Arm Title

Lenalidomide 2

Arm Type

Experimental

Arm Description

Open label lenalidomide received.

Intervention Type

Drug

Intervention Name(s)

Lenalidomide

Primary Outcome Measure Information:

Title

Cutaneous Lupus Area and Severity Index (CLASI)

Description

The Cutaneous Lupus Area and Severity Index (CLASI); range of disease activity is 0-70. Lower scores reflect less activity.

Time Frame

Weeks 0 through 52

Secondary Outcome Measure Information:

Title

Number of Participants With Change in IFN and CD4 Levels at 6 Weeks

Description

CXCL10, an interferon-inducible chemokine, and immunophenotyping by immunostaining. Measurement of interferon-inducible genes from peripheral blood mononuclear cells before and after treatment.

Time Frame

6 weeks

Title

Physician Global Assessment (PGA) for Skin

Description

General skin scores were recorded on a 10 cm visual analogue scale at each visit. At each visit on scale 0-10, 0 corresponding to worst skin condition imaginable and 10 to perfect health.

Time Frame

Weeks 0 through 52

Title

Patient General Assessment (PtGA) for Skin

Description

Time Frame

Weeks 0 through 52

Title

Pain in Skin

Description

Pain in skin was recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no pain and 10 to pain as bad as you can imagine.

Time Frame

Weeks 0 through 52

Title

Itch in Skin

Description

Itch scores were recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no itch and 10 to itch as bad as you can imagine.

Time Frame

Weeks 0 through 52

Title

Fatigue

Description

Fatigue scores were recorded on a 10 cm visual analogue scale at each visit by the patient. At each visit on scale 0-10, 0 corresponding to no fatigure and 10 to fatigue as bad as you can imagine.

Time Frame

Weeks 0 through 52

Title

Skindex Symptoms

Description

Time Frame

Weeks 0 through 52

Title

Skindex Function

Description

Time Frame

Weeks 0 through 52

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

100 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Subjects must understand and voluntarily sign Informed Consent and HIPAA forms. Males and females over the age of 18 at the time of signing informed consent form. Able to adhere to the study visit schedule and other protocol requirements Subjects must have biopsy proven Cutaneous Lupus Erythematosus (CLE) either in the form of Discoid Lupus Erythematosus (DLE) or Subacute Lupus Erythematosus (SCLE), with or without systemic involvement. Subjects must have grade II erythema in at least three skin locations as defined by the Cutaneous Lupus Activity and Severity Index (CLASI). Subjects must have failed standard treatment with hydroxychloroquine (Plaquenil) for up to three months. Female subjects who are not pregnant. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to and again within 24 hours of starting lenalidomide and must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional method AT THE SAME TIME, at least 28 days before starting to take lenalidomide (Revlimid®). FCBP must also agree to ongoing pregnancy testing. Males must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All subjects must be counseled at a minimum of every 28 days about pregnancy precautions and risks of fetal exposure. If pregnancy or a positive pregnancy test is noted in a study subject or in the partner of a male study subject during study participation, the study drug must be discontinued immediately. Exclusion Criteria: Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent the subject from signing the informed consent form. Female subjects who are pregnant, plan to be pregnant during the study, or who are breastfeeding. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk for study participation, or confounds the ability to interpret data from the study. Use of any other experimental drug or therapy within 28 days of baseline. Known hypersensitivity to thalidomide. The development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs. Prior history of deep vein thrombosis (DVT). Prior history of pulmonary embolus (PE). Known positive for HIV viral DNA by qPCR. Positive hepatitis B surface antigen, or hepatitis C. Platelet count < 50,000/mcL. Absolute neutrophil count < 750/mcL Lymphopenia < 500/mcL. Have current signs or symptoms of severe progressive or uncontrolled renal disease (creatinine ≥1.5 x ULN). If female, unwillingness to use one highly effective method and one additional method of birth control. If male, unwillingness to use a latex condom during intercourse with females of childbearing potential. Continued therapy with thalidomide.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Victoria P Werth, MD

Organizational Affiliation

University of Pennsylvania, Department of Dermatology

Official's Role

Principal Investigator

Facility Information:

Facility Name

Hospital of the University of Pennsylvania, Department of Dermatology

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19104

Country

United States

12. IPD Sharing Statement

Citations:

PubMed Identifier

24528907

Citation

Okon L, Rosenbach M, Krathen M, Rose M, Propert K, Okawa J, Werth V. Lenalidomide in treatment-refractory cutaneous lupus erythematosus: Efficacy and safety in a 52-week trial. J Am Acad Dermatol. 2014 Mar;70(3):583-4. doi: 10.1016/j.jaad.2013.11.007. No abstract available.

Results Reference

derived

Learn more about this trial

Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)

We'll reach out to this number within 24 hrs